ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treat…
| Periodo | 2027-03 | 2026-09 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-1.47 | $-0.61 | $-2.66 |
| Estimado | — | $-0.61 | $-0.85 | $-0.98 |
| Sorpresa | — | -141.0% | +28.2% | -171.4% |
| Métrica | ABVX.PA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -73.8% | -39.2% | -34.7% |
| ROA | -57.5% | -30.9% | -26.6% |
| Current Ratio | 8.75 | 2.73 | +6.02 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -57.5% | — |
| ✗Flujo de caja operativo positivo | −€161M | −€154M |
| ✓Rentabilidad sobre activos al alza | -57.5% | -85.9% |
| ✓Caja operativa/activos supera al ROA | -27.6% | ROA -57.5% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 8.75 | 1.82 |
| ✗Sin aumentar el nº de acciones | 70M | 63M |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | -47.2% |
ABIVAX cotiza a 78.95 EUR y tiene una capitalización bursátil de €6.9B. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud